TABLE 2.

Pharmaceuticals that have been evaluated for management of feline asthma

Pharmaceutical	Class	Dose	Outcome	References
Cyproheptadine	Antiserotonergic	2–8 mg PO q12h	No difference in functional or inflammatory parameters compared with placebo	Reinero et al 52 Schooley et al 53
Cetirizine	Antihistamine	5 mg PO q12h	No difference in inflammatory parameters compared with placebo	Schooley et al 53
Zafirlukast	Antileukotriene	10 mg PO q12h	No difference in inflammatory parameters compared with placebo	Reinero et al 52
Cyclosporine	T cell and mast cell inhibitor	10 mg/kg PO q12h	Inhibition of airway hyperresponsiveness and cytological and histological alterations but not mast cell degranulation	Padrid et al 54 Mitchell et al 55
Salmeterol/fluticasone	LABA/glucocorticoid	100/500 μg via inhalation q12h	Significant decrease in functional and inflammatory parameters compared with pretreatment	Leemans et al 56
Racemic albuterol	Short-acting β2-adrenergic agonist	2 mg/kg via inhalation q12h	Significant increase in inflammatory parameters compared with placebo	Reinero et al 46

LABA = long-acting β₂-adrenergic agonist